Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
50
ATAI Quote, Financials, Valuation and Earnings
Last price:
$2.79
Seasonality move
:
-24.68%
Day range:
$2.59 - $2.71
52-week range:
$1.03 - $2.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
238.41x
P/B ratio:
3.56x
Volume:
2.3M
Avg. volume:
4.9M
1-year change:
64.63%
Market cap:
$540.9M
Revenue:
$308K
EPS (TTM):
-$0.91
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
-- | -$0.12 | -100% | -69.44% | $9.83 |
|
BNTX
BioNTech SE
|
$172.6M | -$2.25 | 23.21% | -34.69% | $136.00 |
|
CVAC
CureVac NV
|
$3.9M | -$0.21 | -75.29% | -39.13% | $4.80 |
|
IFRX
InflaRx NV
|
$24.7K | -$0.23 | 256.48% | -10.49% | $3.62 |
|
IMTX
Immatics NV
|
$13M | -$0.36 | -35.38% | -96.4% | $14.33 |
|
MNMD
Mind Medicine
|
-- | -$0.36 | -- | -39.74% | $24.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
$2.70 | $9.83 | $540.9M | -- | $0.00 | 0% | 238.41x |
|
BNTX
BioNTech SE
|
$112.49 | $136.00 | $27B | 191.55x | $0.00 | 0% | 9.12x |
|
CVAC
CureVac NV
|
$5.48 | $4.80 | $1.2B | 6.07x | $0.00 | 0% | 2.14x |
|
IFRX
InflaRx NV
|
$0.85 | $3.62 | $57.6M | -- | $0.00 | 0% | 280.79x |
|
IMTX
Immatics NV
|
$6.13 | $14.33 | $745.1M | 42.21x | $0.00 | 0% | 4.47x |
|
MNMD
Mind Medicine
|
$8.58 | $24.50 | $648.2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
13.53% | 5.441 | 8.75% | 3.50x |
|
BNTX
BioNTech SE
|
1.53% | 1.572 | 1.45% | 9.86x |
|
CVAC
CureVac NV
|
-- | 1.687 | -- | 7.39x |
|
IFRX
InflaRx NV
|
-- | 1.115 | -- | 3.85x |
|
IMTX
Immatics NV
|
-- | 0.442 | -- | 9.87x |
|
MNMD
Mind Medicine
|
-- | 1.549 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
-- | -$20.3M | -81.4% | -92.32% | -1634.02% | -$18.1M |
|
BNTX
BioNTech SE
|
$104.2M | -$562M | -3.86% | -3.91% | -225.11% | -$1.5B |
|
CVAC
CureVac NV
|
$18.9K | -$57.6M | 32.68% | 32.68% | -5747.14% | -$44.1M |
|
IFRX
InflaRx NV
|
-$9.8K | -$13.7M | -56.78% | -56.78% | 1207051.66% | -$14.8M |
|
IMTX
Immatics NV
|
-- | -$37.2M | -4.67% | -4.67% | -218.49% | -$39.3M |
|
MNMD
Mind Medicine
|
-- | -$32.2M | -- | -- | -- | -$29.4M |
ATAI Life Sciences NV vs. Competitors
-
Which has Higher Returns ATAI or BNTX?
BioNTech SE has a net margin of -1699.74% compared to ATAI Life Sciences NV's net margin of -227.46%. ATAI Life Sciences NV's return on equity of -92.32% beat BioNTech SE's return on equity of -3.91%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.15 $176.1M BNTXBioNTech SE54.16% -$1.82 $20.8B -
What do Analysts Say About ATAI or BNTX?
ATAI Life Sciences NV has a consensus price target of $9.83, signalling upside risk potential of 264.2%. On the other hand BioNTech SE has an analysts' consensus of $136.00 which suggests that it could grow by 20.9%. Given that ATAI Life Sciences NV has higher upside potential than BioNTech SE, analysts believe ATAI Life Sciences NV is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV7 0 0 BNTXBioNTech SE14 5 0 -
Is ATAI or BNTX More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.283, suggesting its more volatile than the S&P 500 by 28.318%.
-
Which is a Better Dividend Stock ATAI or BNTX?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or BNTX?
ATAI Life Sciences NV quarterly revenues are $1.6M, which are smaller than BioNTech SE quarterly revenues of $192.3M. ATAI Life Sciences NV's net income of -$26.4M is higher than BioNTech SE's net income of -$437.5M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is 238.41x versus 9.12x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV238.41x -- $1.6M -$26.4M BNTXBioNTech SE9.12x 191.55x $192.3M -$437.5M
-
Which has Higher Returns ATAI or CVAC?
CureVac NV has a net margin of -1699.74% compared to ATAI Life Sciences NV's net margin of -5832.47%. ATAI Life Sciences NV's return on equity of -92.32% beat CureVac NV's return on equity of 32.68%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.15 $176.1M CVACCureVac NV2.02% -$0.24 $699.9M -
What do Analysts Say About ATAI or CVAC?
ATAI Life Sciences NV has a consensus price target of $9.83, signalling upside risk potential of 264.2%. On the other hand CureVac NV has an analysts' consensus of $4.80 which suggests that it could fall by -12.37%. Given that ATAI Life Sciences NV has higher upside potential than CureVac NV, analysts believe ATAI Life Sciences NV is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV7 0 0 CVACCureVac NV1 5 0 -
Is ATAI or CVAC More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ATAI or CVAC?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or CVAC?
ATAI Life Sciences NV quarterly revenues are $1.6M, which are larger than CureVac NV quarterly revenues of $939.6K. ATAI Life Sciences NV's net income of -$26.4M is higher than CureVac NV's net income of -$54.8M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while CureVac NV's PE ratio is 6.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is 238.41x versus 2.14x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV238.41x -- $1.6M -$26.4M CVACCureVac NV2.14x 6.07x $939.6K -$54.8M
-
Which has Higher Returns ATAI or IFRX?
InflaRx NV has a net margin of -1699.74% compared to ATAI Life Sciences NV's net margin of -14092.9%. ATAI Life Sciences NV's return on equity of -92.32% beat InflaRx NV's return on equity of -56.78%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.15 $176.1M IFRXInflaRx NV-5376.61% -$0.14 $63.9M -
What do Analysts Say About ATAI or IFRX?
ATAI Life Sciences NV has a consensus price target of $9.83, signalling upside risk potential of 264.2%. On the other hand InflaRx NV has an analysts' consensus of $3.62 which suggests that it could grow by 325.65%. Given that InflaRx NV has higher upside potential than ATAI Life Sciences NV, analysts believe InflaRx NV is more attractive than ATAI Life Sciences NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV7 0 0 IFRXInflaRx NV5 1 0 -
Is ATAI or IFRX More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.291, suggesting its more volatile than the S&P 500 by 29.054%.
-
Which is a Better Dividend Stock ATAI or IFRX?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or IFRX?
ATAI Life Sciences NV quarterly revenues are $1.6M, which are larger than InflaRx NV quarterly revenues of -$450. ATAI Life Sciences NV's net income of -$26.4M is lower than InflaRx NV's net income of -$8.7M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is 238.41x versus 280.79x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV238.41x -- $1.6M -$26.4M IFRXInflaRx NV280.79x -- -$450 -$8.7M
-
Which has Higher Returns ATAI or IMTX?
Immatics NV has a net margin of -1699.74% compared to ATAI Life Sciences NV's net margin of -214.48%. ATAI Life Sciences NV's return on equity of -92.32% beat Immatics NV's return on equity of -4.67%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.15 $176.1M IMTXImmatics NV-- -$0.35 $580.8M -
What do Analysts Say About ATAI or IMTX?
ATAI Life Sciences NV has a consensus price target of $9.83, signalling upside risk potential of 264.2%. On the other hand Immatics NV has an analysts' consensus of $14.33 which suggests that it could grow by 133.82%. Given that ATAI Life Sciences NV has higher upside potential than Immatics NV, analysts believe ATAI Life Sciences NV is more attractive than Immatics NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV7 0 0 IMTXImmatics NV7 0 0 -
Is ATAI or IMTX More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immatics NV has a beta of 0.811, suggesting its less volatile than the S&P 500 by 18.925%.
-
Which is a Better Dividend Stock ATAI or IMTX?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or IMTX?
ATAI Life Sciences NV quarterly revenues are $1.6M, which are smaller than Immatics NV quarterly revenues of $19.6M. ATAI Life Sciences NV's net income of -$26.4M is higher than Immatics NV's net income of -$41.9M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is 238.41x versus 4.47x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV238.41x -- $1.6M -$26.4M IMTXImmatics NV4.47x 42.21x $19.6M -$41.9M
-
Which has Higher Returns ATAI or MNMD?
Mind Medicine has a net margin of -1699.74% compared to ATAI Life Sciences NV's net margin of --. ATAI Life Sciences NV's return on equity of -92.32% beat Mind Medicine's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.15 $176.1M MNMDMind Medicine-- -$0.35 -- -
What do Analysts Say About ATAI or MNMD?
ATAI Life Sciences NV has a consensus price target of $9.83, signalling upside risk potential of 264.2%. On the other hand Mind Medicine has an analysts' consensus of $24.50 which suggests that it could grow by 185.55%. Given that ATAI Life Sciences NV has higher upside potential than Mind Medicine, analysts believe ATAI Life Sciences NV is more attractive than Mind Medicine.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV7 0 0 MNMDMind Medicine6 0 0 -
Is ATAI or MNMD More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mind Medicine has a beta of 2.803, suggesting its more volatile than the S&P 500 by 180.283%.
-
Which is a Better Dividend Stock ATAI or MNMD?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mind Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. Mind Medicine pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or MNMD?
ATAI Life Sciences NV quarterly revenues are $1.6M, which are larger than Mind Medicine quarterly revenues of --. ATAI Life Sciences NV's net income of -$26.4M is lower than Mind Medicine's net income of -$23.3M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while Mind Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is 238.41x versus -- for Mind Medicine. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV238.41x -- $1.6M -$26.4M MNMDMind Medicine-- -- -- -$23.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
